Century Therapeutics (IPSC) Liabilities and Shareholders Equity (2020 - 2026)

Century Therapeutics (IPSC) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $326.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 3.47% year-over-year to $326.6 million; the TTM figure through Mar 2026 stood at $1.1 billion (down 26.75% YoY), while the FY2025 annual figure was $223.7 million, down 36.67% from the prior year.
• Liabilities and Shareholders Equity grew to $326.6 million in Q1 2026 per IPSC's latest filing, from $223.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $550.3 million in Q1 2022 and bottomed at $223.7 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $389.1 million across 5 years, with a median of $388.6 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity increased 11.24% — and 2025, when it sank 37.03%.
• Century Therapeutics' Liabilities and Shareholders Equity stood at $486.5 million in 2022, then fell by 25.87% to $360.7 million in 2023, then retreated by 2.07% to $353.2 million in 2024, then slumped by 36.67% to $223.7 million in 2025, then jumped by 45.98% to $326.6 million in 2026.
• Business Quant data shows IPSC's Liabilities and Shareholders Equity at $326.6 million in Q1 2026, $223.7 million in Q4 2025, and $244.7 million in Q3 2025.